First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
作者信息
Hanna Caroline, Pettersen Kenneth, Pedley Nathaniel
机构信息
Department of Medicine, Olive View-UCLA Medical Center, Los Angeles County Department of Health Services, Los Angeles, California.
出版信息
Ann Intern Med. 2023 Apr;176(4):eL230006. doi: 10.7326/L23-0006.
DOI:10.7326/L23-0006
PMID:37068293
Abstract
摘要
相似文献
1
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.2型糖尿病的一线治疗：使用钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂
Ann Intern Med. 2023 Apr;176(4):eL230006. doi: 10.7326/L23-0006.
2
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.2型糖尿病的一线治疗：使用钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂
Ann Intern Med. 2023 Apr;176(4):eL230007. doi: 10.7326/L23-0007.
3
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.2型糖尿病的一线治疗：使用钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂
Ann Intern Med. 2023 Apr;176(4):eL230005. doi: 10.7326/L23-0005.
4
Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?在治疗糖尿病时，我们应该联合使用GLP-1受体激动剂和SGLT2抑制剂吗？
Am J Med. 2018 May;131(5):461-463. doi: 10.1016/j.amjmed.2017.11.052. Epub 2018 Jan 5.
5
Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes.2型糖尿病中使用钠-葡萄糖协同转运蛋白2抑制剂和/或胰高血糖素样肽-1受体激动剂的肾脏和心血管结局
J Am Coll Cardiol. 2024 Aug 20;84(8):709-711. doi: 10.1016/j.jacc.2024.07.002.
6
Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.胰高血糖素样肽-1 受体激动剂或钠-葡萄糖共转运蛋白-2 抑制剂作为 2 型糖尿病患者的附加治疗：替代代谢终点的系统评价和荟萃分析。
Diabetes Metab. 2020 Sep;46(4):272-279. doi: 10.1016/j.diabet.2020.04.001. Epub 2020 May 8.
7
A practical review of diabetes mellitus type 2 treatment in primary care.2 型糖尿病的基层医疗实用治疗综述。
Rom J Intern Med. 2022 Mar 17;60(1):14-23. doi: 10.2478/rjim-2021-0031. Print 2022 Mar 1.
8
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂治疗 2 型糖尿病：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573.
9
Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study.GLP-1 受体激动剂和 SGLT2 抑制剂联合治疗 2 型糖尿病老年患者的真实世界证据研究。
Can J Diabetes. 2019 Apr;43(3):186-192. doi: 10.1016/j.jcjd.2018.09.001. Epub 2018 Sep 8.
10
Regional socioeconomic deprivation associated with the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes in Germany.德国2型糖尿病成年患者中与使用钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂相关的区域社会经济剥夺情况
Diabetes Obes Metab. 2024 Sep;26(9):4116-4120. doi: 10.1111/dom.15741. Epub 2024 Jul 9.
Zotero 插件